Knight Therapeutics Inc. updated revenue guidance for fiscal 2022. For the year company has updated its guidance and expects to generate $265 to $275 million in revenue, an increase of $5 million on the lower and upper range.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.44 CAD | +0.18% | -1.09% | +4.82% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.82% | 401M | |
+15.93% | 77.46B | |
+15.49% | 8.94B | |
-24.00% | 4.28B | |
+13.37% | 4.18B | |
+31.17% | 4.11B | |
+9.37% | 2.23B | |
-34.04% | 2.06B | |
+7.66% | 1.97B | |
-48.29% | 1.69B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Updates Revenue Guidance for Fiscal 2022